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The loss of neurons and degeneration of axons after
spinal cord injury result in the loss of sensory and motor
functions. A bridging biomaterial construct that allows
the axons to grow through has been investigated for
the repair of injured spinal cord. Due to the hostility of
the microenvironment in the lesion, multiple conditions
need to be fulfilled to achieve improved functional
recovery. A scaffold has been applied to bridge the gap
of the lesion as contact guidance for axonal growth and
to act as a vehicle to deliver stem cells in order to
modify the microenvironment. Stem cells may improve
functional recovery of the injured spinal cord by
providing trophic support or directly replacing neurons
and their support cells. Neural stem cells and
mesenchymal stem cells have been seeded into
biomaterial scaffolds and investigated for spinal cord
regeneration. Both natural and synthetic biomaterials
have increased stem cell survival in vivo by providing
the cells with a controlled microenvironment in which
cell growth and differentiation are facilitated. This
optimal multi‐disciplinary approach of combining
biomaterials, stem cells, and biomolecules offers a
promising treatment for the injured spinal cord.nerve growth factors should be sustained. The theoreticalIntroduction
Traumatic injury or disease may result in spinal cord in-
jury (SCI). Generally, a complete injury refers to the
total loss of motor or sensory functions pertaining to the
spinal column below the injury site, while an incomplete
injury refers to the retention of some functions. The loss
of neurons and degeneration of axons result in the loss
of function. Because of the severity of SCI, no effective
treatment has ever been formulated. Although therapy
using high doses of methylprednisolone has been* Correspondence: li.yao@wichita.edu
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2014clinically practiced and more drugs are awaiting clinical
trials [1-3], some studies have shown that methylpred-
nisolone treatment results in only weak neurological im-
provement after SCI [4,5].
The central nervous system (CNS) and peripheral ner-
vous system (PNS) differ greatly in regenerative capacity
after an injury [6-9]. In the PNS, nerve tissue is more
likely to regenerate and regain functionality compared
with the CNS [10-13]. Proliferating Schwann cells, mac-
rophages, and monocytes work together to remove mye-
lin debris, while leading axons to their synaptic targets.
Growth-promoting cytokines secreted by Schwann cells
can also support nerve growth [10]. However, the CNS
offers significant challenges when axons regenerate
across the injured site because the glial scars composed
of myelin, cellular debris, astrocytes, oligodendrocytes,
and microglia hinder the regeneration of axons toward
their synaptic targets [11-13]. Additionally, unlike the
PNS, the spinal cord lacks endoneurium or perineurium
equivalents that act as conduits between axonal groups.
The microenvironment at a spinal cord injury site is
complicated, and more than one process needs to be regu-
lated in order for axonal regrowth to occur. Not only
should hindering factors, such as gliosis or inflammation,
be minimized, but the controlled release of necessary
approach to repairing an injured spinal cord is to regener-
ate damaged axons through the site of injury [14-17]. A
bridging biomaterial construct and contact-mediated
guidance for aligned axon growth across the site of injury
into the distal host tissue could potentially allow func-
tional recovery [18]. Due to the inhibiting microenviron-
ment and the lack of sufficient neurotrophic support in
the lesion, multiple conditions need to be fulfilled to
achieve functional recovery. A recent study showed that
neural stem cells (NSCs) expressing green fluorescent pro-
tein were embedded into fibrin matrices containing a
group of growth factors, and the matrices were then
grafted to severely injured rat spinal cords [19]. The
grafted cells differentiated into neurons that formedl Ltd. The licensee has exclusive rights to distribute this article, in any medium,
this time, the article is available under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
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tional recovery of the spinal cord. The promising outcome
of this study suggested that the combined application of
biomaterial scaffolds and stem cells may offer significant
support for functional recovery following SCI. A scaffold
not only bridges the gap of the lesion for contact guidance
but also acts as a vehicle to deliver stem cells and biomol-
ecules to favorably modify the microenvironment at the
injured site [20] (Figure 1).
Here we review recent advances in biomaterial scaf-
folds and their applications as stem cell carriers for
repairing injured spinal cord. First, we focus on studies
of spinal cord repair using a variety of natural and syn-
thetic biomaterial scaffolds. Then we review the com-
bined effect of biomaterial scaffolds and NSCs or
mesenchymal stem cells (MSCs) on spinal cord repair.
Enhancing axonal regeneration of injured spinal
cord using biomaterial scaffolds
While the axons of injured spinal cord have regenerative
potential, they are hindered by various pathophysio-
logical changes and complications following an injury.
As a remedy to overcome this hurdle, neural tissue en-
gineering has received considerable attention in recent
years. A biomaterial scaffold synthesized from either a
natural or synthetic polymer can help prevent the for-
mation of scar tissue and concentrate neurotrophic
growth factors while promoting axonal regeneration be-
tween the two ends of the injured neural tissue [21,22].
The sprouting axons from either damaged or sparedFigure 1 Neural conduits delivering stem cells enhance spinal cord axo
guidance for axonal regeneration and act as carriers for stem cell transplantati
(light blue) that myelinate regenerated spinal cord axons (green). (B) Inhibitiopathways may grow through the scaffolds to reconnect
with the neurons on the caudal side of the lesion and
reconstitute the circuitry. Many strategies have been
investigated to functionalize the scaffolds to create a
permissive microenvironment for axonal regeneration.
Design of biomaterial scaffolds for spinal cord
repair
It has been a scientific challenge to generate the ideal
biomaterial to repair an injured spinal cord. The follow-
ing parameters need to be considered when fabricating
implantable scaffolds to treat SCI.
Biocompatibility
Because contact-mediated guidance of the scaffolds pro-
motes axonal regeneration, biocompatibility is a critical
factor for axonal growth. To enhance axonal growth,
biological molecules, such as full-length proteins or
shorter peptide chains, have been conjugated on the sur-
face of the scaffold to mimic a natural extracellular
matrix [22].
Biodegradability
Biomaterial scaffolds temporarily support axonal regen-
eration and should degrade over time once that purpose
has been met. The degradation rate of scaffolds should
be manipulated in such a manner that they are digested
by existing enzymes in the body as the nerves regener-
ate. The need for secondary surgery to remove scaffolds
may cause further complications [19].nal regeneration. (A) Neural conduits simultaneously provide structural
on. Stem cells differentiate into neurons (dark blue) and oligodendrocytes
n of axonal regeneration by glial scar after spinal cord injury.
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Repetitive compressive force and degradation via en-
dogenous reactive cells pose an external mechanical
stress to scaffolds. Scaffolds should not only support
axonal regeneration before disintegration but also with-
stand those forces generated from the spine and sur-
rounding muscles. Various methods such as crosslinking
and optimization of the material composition have been
used to improve the mechanical properties of biomate-
rials [22,23]. Due to soft and flexible mechanical proper-
ties similar to those of the spinal cord, hydrogel has
been used in SCI and has been shown to cause little
mechanical stress to the surrounding tissue.
Scaffold morphology
Axially oriented pores, channels, and aligned fibers help
direct the growth of neural structures [24]. A continu-
ous, porous structure that resembles a natural matrix of-
fers a favorable environment for axonal regeneration.
Well-calculated porosity in scaffolds favors cellTable 1 Repair of injured spinal cord using biomaterial scaffo
Injury Animal
model
SCI
stagea
Scaffold
Complete transection
(mid thoracic)
Rat Acute Collagen single channel tube
Complete transection
(T9)
Rat Acute Fibrin beads
Hemisection (T7-T9) Rat Acute Fibronectin mat
Hemisection (T7-T9) Rat Acute Fibrin/fibronectin gel
Complete transection
(C4)
Rat Acute Agarose multichannel tube
Complete transection
(T3)
Rat Acute Agarose multichannel
honeycomb structure
Hemisection (C3) Rat Acute Agarose multichannel tube
Compression (T9) Rat Acute Hyaluronic acid hydrogel
Hemisection (T8-T9) Rat Acute Hyaluronic acid hydrogel
Compression (T12-L1) Guinea
pig
Acute Chitosan injectable solution
Complete transection
(T9)
Rat Acute Chitosan single channel tube
Complete transection
(C6-C7)
Rat Acute Self-assembled peptide
nanofiber
Compression (T2) Rat Acute Hyaluronan and methyl
cellulose hydrogel blend
Hemisection (C3-C4) Rat Acute Poly-β-hydroxybutyrate single
channel tube
Complete transection
(T8)
Rat Acute PHEMA-co-MMA hydrogel
Complete transection
(T9-T10)
Rat Acute PLA macroporous sponge
aAcute refers to implantation of scaffolds with cells immediately after injury. PHEMA
cord injury.attachment and is critical in allowing greater distances
to be bridged [25]. Highly porous structures offer a lar-
ger surface area for cell attachment. Porosity and pore
size also determine the flow of different constituents that
promote or suppress nerve regeneration.
Internal matrices
Internal matrices in nerve-guidance channels allow the
channel to mimic the molecular component and
organization of the microenvironment naturally found in
neural tissues as well as the bioactivity while promoting
axonal growth [22].
Natural polymer-based scaffolds
Collagen, a widely used biomaterial, is both biocompat-
ible and biodegradable [26]. In one study, completely
transected spinal cord stumps of rats were bridged by
collagen tubes, and the results showed aligned axon
growth within the tube lumen and a reduction in the
density of glial scar formation [27] (Table 1). In a rabbitlds
Outcome Reference
Significant axonal regeneration in tube and reduced
scar invasion
[27]
Increased axonal fiber density along injury site [29]
Considerable axonal growth along implant site [30]
Axonal growth observed [31]
Axonal regeneration along lesion site [32]
Linear axonal regeneration along injury site [33]
Linear axonal regeneration and significant linear axonal
growth
[34]
Axon proliferation and motor function improvement [35]
Increased axonal regeneration and inhibition of scar
formation
[36]
Partial restoration of somatosensory- evoked potential [37]
Axonal regeneration and partial locomotor functional
recovery of hind limbs
[38]
Axonal regeneration [18]
Host axon survival and functional improvement [39]
Axonal regeneration along conduit [40]
Axonal regeneration [41]
Myelinated axon regeneration and gradual functional
recovery in hind limb motion
[42]
-co-MMA, poly 2-hydroxyethyl methacrylate; PLA, polylactic acid; SCI, spinal
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the rabbit spinal cord with a 3-mm defect. Axons regen-
erated across the distal and proximal ends of the im-
plants. Improved functional recovery in the locomotor
rating scale was seen in the grafted group compared
with the non-treated control group [28].
Fibrin is a fibrous and non-globular protein that helps
in blood clotting and has been used extensively as a bio-
polymer scaffold in tissue engineering [43]. Scaffolds fab-
ricated from fibrin delivering neurotrophic growth
factors were applied in the treatment of a rat SCI model,
and the study showed improved axonal growth [44]. Fi-
brin scaffolds containing neurotrophin (NT)-3 enhanced
neural fiber sprouting when the rats received a delayed
treatment 2 weeks following the SCI. In another study,
fibronectin was fabricated into fibronectin mats and im-
planted into a wounded spinal cord that had a portion
of the spinal cord removed (1 mm laterally from the
midline and 1 mm ventrally from the surface of the
spinal cord) [30]. Results showed that the mats sup-
ported myelinated axonal growth. Fibronectin shows a
better cell-attachment function than fibrin and offers
beneficial neuroprotective properties. However, fibronec-
tin does not aggregate as easily as fibrin for gel forma-
tion. Interestingly, a blend of fibrin and fibronectin
achieved in situ gel formation and improved cell attach-
ment and proliferation [31]. The injured spinal cord im-
planted with this mixture showed improved tissue
integration and axonal growth.
Agarose is a biocompatible material and can withstand
biodegradation over a month in vivo. Agarose can be fab-
ricated as a scaffold with guidance pores, and the scaffolds
are stable under physiological conditions without the need
for crosslinking [34]. Agarose scaffolds containing a brain-
derived neurotrophic factor (BDNF) have been used to
treat complete transected spinal cord and have shown sig-
nificant axonal regeneration [33]. In one study, freeze-
dried agarose scaffolds with uniaxial channels were im-
planted into an injured rat spinal cord [34]. This study
showed that the agarose scaffolds were well integrated
into the host tissue, and aligned axonal growth was ob-
served in the scaffolds 1 month after surgery.
Hyaluronic acid (hyaluronan), a glycosaminoglycan, is a
major component of the extracellular matrix. Crosslinked
high molecular weight hyaluronic hydrogels were im-
planted in rat spinal cords with dorsal hemisection injury
[45]. Hyaluronic acid reduced the cell proliferation of the
astrocytes and thus helped attenuate the inflammatory re-
sponse and gliosis in the surrounding tissue. In another
study, hyaluronic acid-based hydrogels modified with poly-
L-lysine and nogo-66 receptor antibody (antiNgR) were
implanted into a rat spinal cord after lateral hemisection
surgery [36]. The scaffolds showed significant advantages in
supporting angiogenesis and inhibiting glial scar formation.Chitosan is a naturally available polysaccharide found
in the exoskeleton of crustaceans and insects. After be-
ing filled with type I collagen, a chitosan tube was im-
planted in a transected spinal cord [38]. The regenerated
axons connected the distal and proximal ends of the le-
sion site, thus leading to functional recovery, as indi-
cated by Basso, Beattie, and Bresnahan evaluation. This
study suggested that chitosan, in combination with colla-
gen, can potentially block glial scar tissue formation and
facilitate the directional projection of axons.
Synthetic polymer-based scaffolds
Poly(lactic-co-glycolic acid) (PLGA), a synthetic copoly-
mer of polylactic acid and polyglycolic acid, is biocompat-
ible and biodegradable. The degradation rate of the
copolymer can be controlled by altering the ratio of poly-
lactic acid and polyglycolic acid [25]. Neural conduits fab-
ricated from PLGA have been implanted into completely
transected rat spinal cord. Axonal regeneration was ob-
served in the channels of the neural conduits [46,47].
However, it was noted that the breakdown of PLGA pro-
duced glycolic and lactic acids, which lowered the local
pH and could hinder the tissue-repair process.
Polycarbonate polymers belong to a group of thermo-
plastic polymers that degrade to non-acidic products. Be-
cause polycarbonates do not adhere to cells due to their
hydrophobic nature, they are normally used in combin-
ation with poly-L-lysine [48]. Poly-L-lysine-coated poly-
carbonate tubes were seeded with Schwann cells, and
these prepared neural tubes were implanted into the
wounded thoracic spinal cord of a rat [49]. Two months
after implantation, axons grew through the tubes.
Poly 2-hydroxyethyl methacrylate (PHEMA-co-MMA)
can be fabricated as scaffolds to mimic the mechanical
properties of the spinal cord. In one study, PHEMA-co-
MMA hydrogels were implanted between the stumps of a
completely transected spinal cord [50]. The hydrogel not
only supported axonal regeneration but also reduced the
formation of necrotic tissue. Poly N-2-hydroxypropyl-
methacrylamide (pHPMA) is a biocompatible polymer
with viscoelastic properties. The macromolecular network
of this polymer is suitable for ingrowth of cells and can
promote diffusion of trophic and growth factors. pHPMA
hydrogel implanted into a hemisected rat spinal cord sup-
ported axon growth [1].
Transplantation of biomaterial scaffolds
delivering stem cells for spinal cord repair
NSCs and MSCs are multi-potent stem cells. NSCs can
mainly differentiate into astrocytes, oligodendrocytes,
and neurons [51], and MSCs can differentiate into a var-
iety of cell types such as osteoblasts, chondrocytes, and
adipocytes [52]. NSCs and MSCs are the two primary
categories of stem cells that have been used jointly with
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generate increased functional recovery of an injured
spinal cord by providing trophic support, promoting en-
dogenous regeneration, or directly replacing neurons
and their support cells [53-55]. Biodegradable polymers
can simultaneously provide structural guidance for
axonal regeneration and be a carrier for stem cell deliv-
ery. Both natural and synthetic biomaterials for cell de-
livery increased cells’ in vivo survival because the
scaffolding provides a controlled microenvironment to
facilitate cell growth and differentiation [47,50,56-60].
Additionally, biomaterials may serve as a vehicle for the
delivery of biomolecules to treat the injured spinal cord.
The optimal multi‐disciplinary approach combining bio-
materials, stem cells, and biomolecules offers a promis-
ing treatment for repairing the injured spinal cord.
Neural stem cells delivered by biomaterial
scaffolds for spinal cord repair
In one study, multi-potent neural cell lines (generated
via retrovirus-mediated transferral of v-myc into murine
cerebellar progenitor cells) were grown in PLGA scaf-
folds, and the scaffolds were used to bridge injured rat
spinal cords with lateral hemisection surgery [61]. The
rats showed improved functional recovery and reduced
scar formation 70 days after the injury and scaffold im-
plantation. In another study, NSCs collected from em-
bryonic rats were seeded into PLGA scaffolds and the
scaffolds implanted into completely transected rat spinal
cords [47] (Table 2). One month after treatment, more
axons were observed in the channels of the scaffolds
with NSCs compared with the scaffold-only group. It
was also shown that the scaffolds enhanced the survival
of the NSCs 8 weeks after implantation. To improve the
low survival and lack of controlled differentiation, mouse
embryo-derived NSCs were grown in fibrin scaffolds
containing platelet-derived growth factor and NT-3 [62],
and the scaffolds were then implanted in rat spinal cords
2 weeks after initial hemisection surgery. Functional re-
covery was observed 4 weeks after implantation.
Implantation of NSCs from post-natal and adult ani-
mals has also shown some success in the treatment of
SCI. Collagen scaffolds were seeded with NSCs har-
vested from the brains of adult rats, and the scaffolds
were implanted into a fully transected rat spinal cord
immediately after the transection surgery [57]. The im-
plantation of the scaffolds decreased cyst formation at
the injury site. In another study, neural stem and precur-
sor cells (NSPCs) from a rat brain or spinal cord were
seeded into chitosan scaffolds for the treatment of in-
jured spinal cords [48]. Scaffolds were implanted into a
completely transected rat spinal cord. Fourteen weeks
after implantation, the group with NSPC implantation
displayed a connection of neural tissue at the injury sitewith a large number of surviving NSPCs. The implanted
stem cells primarily differentiated into astrocytes and ol-
igodendrocytes. Bozkurt and colleagues [56] implanted
NSPC-seeded chitosan channels into a rat spinal cord
3 weeks after extradural compression injury. In the con-
trol group, NSPCs were directly injected into the injured
spinal cord. Six weeks after transplantation, the group
with scaffold implantation showed a higher number of
surviving NSCs at the injury site compared with the
cell-injection groups. In a more clinically relevant model
of SCI, Pritchard and colleagues [69] performed a hemi-
section injury on the spinal cord of an African green
monkey, and PLGA scaffolds seeded with human NSCs
were implanted into the spinal cord immediately after
the surgery. Scaffolds in the implanted subjects persisted
for at least 40 days, which provided ample time for the
implanted human NSCs to divide and differentiate. This
study provided a primate model of SCI to investigate the
therapeutic effects of scaffold and stem cells.
Mesenchymal stem cells delivered by biomaterial
scaffolds for spinal cord repair
An increasing amount of research demonstrates the cap-
acity of MSCs to regenerate an injured spinal cord
[70-74]. In contrast with embryonic and fetal tissues,
MSCs are an easily obtained source of stem cells. They
are most commonly harvested from bone marrow but
are also available from other sources, such as adipose
tissue and umbilical cords. Because MSCs are easily ob-
tained from an autologous cell source, the possible risk
of an immune response against the implanted tissues is
greatly lowered. Zeng and colleagues [20] implanted an
MSC-seeded gelatin scaffold into transected rat spinal
cord (Table 3). Eight weeks after treatment, they found
that the implantation of scaffolds with MSCs reduced
the cavity area of the injured spinal cord. Additionally,
there was a decrease in reactive macrophages and micro-
glial cells. This supports the concept of immunosuppres-
sive effects of MSCs, which is an important factor for
the successful treatment of SCIs. In a xenotransplant-
ation study, a PLGA/small intestinal submucosa scaffold
seeded with human bone marrow stem cells (BMSCs)
was implanted into completely transected rat spinal cord
[59]. Behavioral and electrophysiological studies were
conducted on the rats for up to 8 weeks post-surgery.
The rats demonstrated an improvement in Basso, Beat-
tie, and Bresnahan score and motor-evoked potentials
8 weeks after surgery. Additionally, histological results
showed that the MSCs were detected in the lesion
8 weeks post-surgery. In another study, MSCs derived
from green fluorescent protein transgenic rats were
seeded in 2-hydroxypropyl methacrylamide-based hydro-
gel to treat SCI with chronic compression [58]. Five
weeks after a balloon compression injury in rat spinal
Table 3 Repair of injured rat spinal cord using biomaterial scaffolds and mesenchymal stem cells
Injury SCI Stage Scaffold Outcome Reference
Complete
transection (T10)
Acute PLGA multichannel conduits Cells integrated well into host tissue [76]
Complete
transection (T8-T9)
Acute PLGA porous scaffolds and
small intestine submucosa
Significant improvement in functional
outcomes, improved greater axon
regeneration
[59]
Transection (T10-11) Acute Gelatin sponge Reduced inflammatory response and cavity
formation, promotion of angiogenesis
[20]
Balloon-induced
compression (T8-T9)
Implantation of scaffolds with cells
5 weeks after original injury
HPMA-RGD hydrogel Significant improvement [58]
HPMA-RGD, N-(2-hydroxypropyl)-methacrylamide with attached amino acid sequence Arg-Gly-Asp; PLGA, poly(lactic-co-glycolic acid).
Table 2 Repair of injured spinal cord using biomaterial scaffolds and neural stem cell cells
Injury Animal
model
SCI stagea Scaffold Stem cell Outcome Reference
Complete
transection (T8-T9)
Rat Acute PLGA
multichannel
conduit
Embryonic
rat NSC
Facilitated regeneration of axons in
channels of scaffold
[47]
Transection (T9-T10) Rat Acute PLGA
multichannel
conduit
Neonatal
rat NSC
Axonal regeneration, NSC
differentiation, functional
improvement
[63]
Hemisection (T9-T10) Rat Acute PLGA-oriented
scaffold
Neonatal
rat NPC
Increase in vessel density, reduced
glial scarring, inflammatory response
[64]
Two hemisections
(T7-8 and L2-3)
Rat Acute PLGA film Human
fetal brain
NSC
Lower rates of human NSC death in films
embedded with reactive oxygen, species
collectors (MnTBAP, UA)
[60]
Hemisection (T7-T8) Rat Acute PCL scaffolds Human
fetal NSC
Implanting NSCs overexpressing NT-3
resulted in increased behavioral and
electro-physiological recovery
[65]
Transection (C6-C7) Acute Self-assembling
peptide
nanofiber
scaffold
Embryonic
NPC
Microenvironment around cells in
the scaffolds, controlled cell
proliferation, differentiation
[66]
Full-resection
(5 mm) of spinal
cord (T8 and T9)
Rat Acute Collagen
gelfoam
Adult rat
NSC
Decrease in scar formation [57]
Complete
transection (T10)
Rat Acute Gelfoam Neonatal
rat NSC
Improved relay of cortical
motor-evoked potential and cortical
somatosensory-evoked
potential
[67]
Complete
transection (T8)
Rat Acute Chitosan
channels
Adult rat
NSPC
Improved survival of NSPCs,
NSPCs differentiated into mature
astrocytes and oligodendrocytes
[48]
Hemisection (T11) Canine Acute PLGA scaffolds Human
NSC
Grafted NSC survived implantation
procedure and showed migratory
behavior to residual spinal cord tissue
[68]
Hemisection (T9) African
green
monkey
Acute PLGA porous
scaffolds
Human
NSC
Behavioral evaluations confirmed
improvement in post-operative paralysis,
model appropriate for future studies
with primates
[69]
Clip compression
injury (T7-T9)
Rat Implantation of scaffolds
with cells 3 weeks after
original injury
Chitosan
channels
Adult rat
spinal
cords
NSPC
Improved survival of seeded
NSPCs in chitosan channel
[56]
aAcute refers to implantation of scaffolds with cells immediately after injury. MnTBAP, manganese (III) tetrakis (4-benzoic acid) porphyrin; NPC, neural precursor
cell; NSC, neural stem cell; NSPC, neural stem and precursor cell; NT, neurotrophin; PCL, poly(ɛ-caprolactone); PLGA, poly(lactic-co-glycolic acid); SCI, spinal cord
injury; UA, uric acid.
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the injured spinal cord. The authors observed increased
functional recovery in the rats treated with hydrogel
seeded with MSCs compared with those treated with
hydrogel alone. In another study, dibutyryl cyclic adeno-
sine monophosphate (dbcAMP) was encapsulated in
PLGA microspheres, which were embedded within oligo
[(polyethylene glycol) fumarate] hydrogel scaffolds [75].
The scaffolds were loaded with MSCs or Schwann cells
and then grafted into the transected rat spinal cord. The
sustained release of dbcAMP inhibited axonal regener-
ation in the presence of Schwann cells but rescued
MSC-induced inhibition of axonal regeneration.
Although both NSCs and MSCs have been used in the
repair of SCI, they have demonstrated different mecha-
nisms in post-SCI functional recovery. After transplant-
ation into the injured spinal cord, NSCs can potentially
differentiate into mature neuronal cells to reconstitute
the neural circuit. However, studies have found that
transplanted NSCs show a preferential capability of dif-
ferentiating into glial lineages, especially astrocytes and
low neuronal differentiation, which could promote astro-
gliosis and extension of the glial scar and result in poor
functional recovery [75,77-79]. It has been reported that
MSCs secrete into SCI lesions multiple pro-survival cy-
tokines, such as insulin-like growth factor, BDNF, and
vascular endothelial growth factor (VEGF) [80]. It has
been shown that the transplantation of MSCs into the
spinal cord post-SCI can downregulate apoptotic and
upregulate anti-apoptotic molecules, which prevented
oligodendrocyte apoptosis-induced demyelination and
axon degeneration [81]. In addition, MSC transplant-
ation regulated the activation of macrophages in the
post-SCI inflammatory environment [20]. Quantitative
histological staining demonstrated that implantation of
human mesenchymal precursor cells into rats with SCI
resulted in more intact spinal tissue and reduced cyst
formation compared with controls [82,83]. However,
limitations of the MSCs in the treatment included lack
of neural differentiation, low survival rate of grafted
cells, and a host immune response [84]. In addition to
NSCs and MSCs, Schwann cells have also been widely
investigated in the treatment of SCI, after which they
migrate from the periphery into the lesion and partici-
pate in repair processes. Grafts of biomaterials loaded
with Schwann cells or Schwann cells alone in injured
spinal cord have shown some success in promoting
axonal regeneration and remyelination [85-88].
Gene-modified stem cells for spinal cord repair
The introduction of therapeutic genes into stem cells is
a strategy to increase the effectiveness of stem cells in
the treatment of injured spinal cord. Fetal NSCs were
genetically modified to express VEGF, which canstimulate the proliferation of endogenous glial progeni-
tor cells [89]. Fetal NSCs retrovirally transduced with
VEGF were transplanted into injured spinal cords of rats
7 days after impact injury. The cells were injected ros-
trally and caudally to the injury site. There was increased
expression of VEGF for up to 6 weeks after injection
and an increase in glial progenitor cells. Hwang and col-
leagues [65] genetically modified human NSCs with the
NT-3 gene and seeded the cells into poly(ɛ-caprolac-
tone) scaffolds. The scaffolds were then placed into the
injured rat spinal cord with hemisection surgery. Nine
weeks after surgery, NT-3-expressing NSCs markedly in-
creased both behavioral and electrophysiological recov-
ery. Furthermore, it was shown that more gene-modified
cells were integrated into the host tissue than non-gene-
modified cells. MSCs have also been genetically modified
to overexpress neurotrophic factors such as NT-3 [90],
BDNF [91], and glial cell line-derived neurotrophic fac-
tor [92]. The transplantation of gene-modified MSCs
into wounded spinal cord promoted axonal regeneration.
In one study, gene-modified human MSCs (hMSCs)
overexpressing BDNF were transplanted into transected
rat spinal cord [91]. Five weeks after transplantation, the
BDNF-hMSC group showed improved locomotor recov-
ery. Additionally, increased sprouting of injured corti-
cospinal tract and serotonergic projections was observed
after BDNF-hMSC transplantation.
Gene modification of stem cells has increased the sur-
vival of implanted cells. In a canine SCI model, NSCs
were retrovirally transduced with the NT-3 gene and
seeded into PLGA scaffolds [68]. The scaffolds were then
implanted into the spinal cord immediately after hemi-
section surgery. Two weeks post-injury and implant-
ation, decreased glial scar formation was observed.
When the tissue was studied 12 weeks after surgery, it
was shown that NT-3 overexpression in the cells im-
proved the cell survival rate.
Gene modification of stem cells has also enhanced
neural differentiation of implanted stem cells. NT-3 and
TrkC genes were introduced into rat-derived NSCs using
adenoviral vectors [63]. The gene-modified cells were
then loaded into PLGA scaffolds, and the scaffolds were
implanted immediately into transected rat spinal cords.
Two months later, neural differentiation and synapto-
genesis of the NSC cells were observed in the scaffolds.
In another study, NSCs and Schwann cells were har-
vested from postnatal rats and genetically modified with
the TrkC gene and NT-3 gene, respectively [67]. The
cells were immediately loaded into gelfoam and
implanted into transected spinal cord. Sixty days after
injury and implantation, the group treated with both
NT-3-expressing Schwann cells and TrkC-expressing
NSC cells showed significant functional improvement and
increased myelination. The differentiated NSCs expressed
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studies support further work using genetically modified
cells as a strategy to increase the survival of implanted
cells and to drive the differentiation of present stem cells
along desired neural lineages.
Limitation in studies of spinal cord injury and
future directions
In the process of axonal regeneration after SCI, functional
recovery may arise from collateral sprouting of either
damaged or spared pathways, which may establish novel
neuronal circuits. Descending propriospinal neurons me-
diate important spinal functions, such as reflex, posture,
and locomotion. The regeneration of descending pro-
priospinal neuron axons may provide an alternative path-
way to transmit supraspinal motor commands to spinal
cord motor neurons. The implantation of biomaterial
scaffolds makes the lesion environment more permissive
to growth and can also provide structural guidance for
axon growth. Although axonal growth in biomaterial scaf-
folds carrying stem cells is encouraging, significant chal-
lenges for spinal cord regeneration still exist. The number
of regenerating axons following SCI is typically low.
Optimization of tropic support is needed to promote
axonal growth [47,88,93-95]. Retrograde tracing for rats
with spinal cord transection and scaffold implantation has
shown that the number of labeled neurons on the rostral
side of a graft is much lower than in the control group
[95]. The graft-host interface presents a growth-inhibitory
environment associated with reactive astrocytes and CNS
myelin. The inhibitory environment prevents the growth
of regenerated axons across the scaffold-host tissue border
and into the host tissue. The barrier needs to be treated to
allow more axons to grow into the host tissue in order to
establish functional connections. However, it is not fully
understood how the regenerated axons reach the appro-
priate target at the caudal side of the scaffolds and estab-
lish functional connections. Further studies need to
address the issue of the appropriate directionality of as-
cending and descending tracts after the repair of an in-
jured spinal cord with biomaterial scaffolds. In addition to
behavior testing, electrophysiological analysis is a robust
method to show connectivity and should be included in
the evaluation of functional recovery.
One of the challenges in the study of SCI is to deter-
mine the most effective treatment at different stages.
Each phase of the injury process has unique challenges
to address, which may result in certain treatments being
more effective at one stage than another. Most of the
studies presented have focused on either the acute or
chronic stage, with few comparing the effectiveness of
treatment across all stages of the injury. While most of
these strategies are applied immediately after injury,
some suggest that a time delay between the injury andthe treatment can generate a positive outcome [44].
NSCs were implanted into the injured spinal cord at
both the subacute (7 days post-injury) and early chronic
stage (21 days post-injury) in a mouse SCI model [96].
The results of this study revealed increased success in
the subacute group, with significant signs of motor re-
covery. This illustrates that the results obtained at one
stage of injury may not be universally applicable. Finally,
injury progression in the chronic stage presents unique
challenges that may require a more aggressive approach.
The complete spinal cord transection model, hemisec-
tion model, and compression injury model have been
used in the investigation of spinal cord repair. One of
the challenges in assessing the effectiveness of biomate-
rials and stem cell therapy as applied to SCI is the lack
of comparative studies combined with the range of
methodologies used. To assess the effectiveness of a par-
ticular treatment in various studies, the type of injury,
grafted biomaterials, and stem cells in these studies
should be consistent.
Conclusion
Engineered biomaterial scaffolds can simultaneously serve
as contact guidance for axonal growth through injured
neural tissue and act as a vehicle to deliver stem cells to
modify the microenvironment. Stem cells may allow for
increased functional recovery of the injured spinal cord by
providing trophic support and directly replacing neurons
and their support cells. NSCs and MSCs have been seeded
into biomaterial scaffolds and investigated for spinal cord
regeneration. Both natural and synthetic biomaterials have
increased the in vivo survival of stem cells by providing
them with a controlled microenvironment to facilitate cell
growth and differentiation. Although the results of the
joint application of biomaterial scaffolds and stem cell
therapy in spinal cord regeneration are encouraging, the
current method for reconstruction of the damaged neural
tissue and functional recovery presents significant limita-
tions. Further investigation is required to establish the
functional connection of regenerated axons through the
glial scar and the appropriate directionality of ascending
and descending tracts.
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